Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289015 | 0.94 | GSK3B (0.54) | GSK3BCHEK1L3MBTL1NAMPTTSHR | |
| SCHEMBL14607249 | 0.93 | GSK3B (0.55) | GSK3BCYP2C19CHEK1NAMPTCDK2 | |
| SCHEMBL13120545 | 0.91 | GSK3B (0.66) | GSK3BCDK2 | |
| SCHEMBL13289097 | 0.89 | GSK3B (0.59) | GSK3BCHEK1NAMPTTSHRCDK2 | |
| SCHEMBL14307160 | 0.89 | GSK3B (0.51) | GSK3BHTTKMT2ACHEK1NAMPT | |
| SCHEMBL13289096 | 0.89 | GSK3B (0.55) | GSK3BCYP2C19KMT2ACHEK1NAMPT | |
| SCHEMBL13289366 | 0.89 | GSK3B (0.55) | GSK3BCHEK1NAMPTTSHRCDK2 | |
| SCHEMBL12953928 | 0.89 | GSK3B (0.55) | GSK3BHTTMEN1POLBKMT2A | |
| SCHEMBL12953927 | 0.89 | GSK3B (0.51) | GSK3BCHEK1NAMPTCDK2 | |
| SCHEMBL14418840 | 0.88 | GSK3B (0.53) | GSK3BCYP2C19CHEK1NAMPTCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | GSK3B 937/4885KDM4E 462/4885CYP1A2 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.